Skip to main content

Merck & Co., Inc. statistics

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Enterprise value$408.5B
EV / EBITDA14.45
EV / sales6.06

Share price

Latest close$147.76
Day's change+0.6%
52-week high$156.92
52-week low$90.90
From 52-week high−5.8%
Return · 1 month+1.2%
Return · 3 months−0.8%
Return · year to date+40.4%
Return · 1 year+61.6%
Beta · 1 year against the S&P 5000.19
50-day average$146.13
200-day average$128.65
RSI 1452.5
Average volume · 20 sessions9.6M

Margins and returns

For fiscal 2025, as filed.

Gross margin74.8%
Operating margin34.5%
Net margin28.1%
Free cash flow margin19.0%
Return on equity36.9%
Return on assets15.3%
Return on invested capital21.9%
Return on capital employed22.7%
Stock-based compensation / revenue1.3%

Financial position

At the end of fiscal 2025.

Cash and equivalents$14.56B
Total debt$50.49B
Net debt$35.93B
Current ratio1.54
Debt / equity0.96
Net debt / EBITDA1.27
Interest coverage16.52

Shares and dividends

For fiscal 2025, as filed.

Diluted shares2.5B
Net share repurchases$4.99B
Dividends per share$3.28
Dividend payout44.8%

Taxes

For fiscal 2025, as filed.

Income tax expense$2.80B
Effective tax rate13.3%

MRK in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.